Cytiva and Forecyte Bio announced on August 25, 2022 that they will collaborate to accelerate the manufacturing and development of the cell and gene therapy industry in China and the United States.
The companies will utilize Cytiva’s Fast Trak center in Shanghai, where biotech companies can access industry knowledge and professional consulting and training. Forectye Bio will use the Shanghai facility and Cytiva’s FlexFactory platforms to launch its contract development and manufacturing organization (CDMO) business and have good manufacturing practice (GMP) production capabilities for virus and plasmid DNA.
